Recommending the Pneumococcal Vaccine at Age 50 Reduces Disease-Related Racial Disparities; But is it Cost-Effective?
Health Sciences at the University of PittsburghIf mitigating racial disparities in those who contract pneumococcal diseases, such as meningitis and pneumonia, is a top public health priority, then recommending that all adults get a pneumococcal vaccine at age 50 would likely be effective guidance.